NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp

Rhea-AI Summary

NAMSA (ARCHIMED portfolio) completed the acquisition of the U.S. assets of Labcorp's Early Development medical device testing business on Jan 8, 2026, expanding NAMSA's U.S. service portfolio to include biocompatibility, microbiological, analytical testing and preclinical research.

The deal positions NAMSA as a broader end-to-end MedTech testing partner, transfers Labcorp Early Development device projects to NAMSA facilities in Ohio, Minnesota, Georgia and California, and is NAMSA's 10th acquisition since joining ARCHIMED in 2020.

Positive

• Adds U.S. portfolio of Labcorp Early Development testing services
• Projects moved to four NAMSA U.S. facilities: Ohio, Minnesota, Georgia, California
• Marks NAMSA's 10th acquisition since joining ARCHIMED in 2020
• NAMSA serves over 3,000 MedTech companies globally

Negative

• None.

News Market Reaction – LH

+0.37%

1 alert

+0.37% News Effect

On the day this news was published, LH gained 0.37%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

MedTech clients served: 3,000+ companies NAMSA acquisitions: 10th acquisition ARCHIMED AUM: €9 billion +2 more

5 metrics

MedTech clients served 3,000+ companies Global MedTech companies using NAMSA services

NAMSA acquisitions 10th acquisition Number of acquisitions since becoming an ARCHIMED company

ARCHIMED AUM €9 billion Assets managed across ARCHIMED funds

NAMSA founding year 1967 Year NAMSA began helping medical device sponsors

ARCHIMED acquisition year 2020 Year NAMSA was acquired by ARCHIMED

Market Reality Check

Price: $269.67 Vol: Volume 602,347 is 1.03x t...

normal vol

$269.67 Last Close

Volume Volume 602,347 is 1.03x the 20-day average of 587,464, only modestly elevated. normal

Technical Shares at $253.73 are trading below the 200-day MA of $258.3 and 13.62% under the 52-week high.

Peers on Argus

LH fell 2.56% while peers were mixed: DGX -1.66%, MTD -0.82%, WAT -0.04%, but NT...

LH fell 2.56% while peers were mixed: DGX -1.66%, MTD -0.82%, WAT -0.04%, but NTRA +0.52% and IQV +1.37%, indicating a stock-specific move rather than a broad sector rotation.

Historical Context

5 past events · Latest: Dec 30 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 30	Conference participation	Neutral	-0.9%	Announcement of J.P. Morgan Healthcare Conference fireside chat participation.
Dec 02	Asset acquisition	Positive	-0.1%	Completion of $194M CHS outreach lab asset acquisition to expand services.
Nov 24	Board appointment	Positive	-0.1%	Appointment of experienced Novartis executive Victor Bulto to board.
Nov 19	Clinical data update	Positive	+0.3%	Positive MRD assay data for Plasma Detect in two peer‑reviewed studies.
Oct 28	Earnings results	Positive	-5.8%	Q3 2025 beat with higher EPS and improved margins but guidance tweak.

Pattern Detected

Recent announcements, including acquisitions, clinical advances and strong earnings, were often followed by flat-to-negative next-day moves, suggesting a pattern of muted or contrary price reactions to positive news.

Recent Company History

Over the past few months, Labcorp reported solid Q3 2025 results with revenue of $3.56B and adjusted EPS of $4.18, yet shares fell 5.79% the next day. Strategic moves included acquiring CHS outreach lab assets and showcasing Plasma Detect clinical data, both framed positively but met with only slight stock moves. Board changes and conference participation were also disclosed with limited price impact, indicating investors have not strongly rewarded recent corporate developments.

Market Pulse Summary

This announcement highlights Labcorp’s sale of its Early Development medical device testing business...

Analysis

This announcement highlights Labcorp’s sale of its Early Development medical device testing business, shifting focus toward core preclinical drug development and chemical testing. Historically, Labcorp has emphasized strategic transactions, including acquisitions, alongside solid operating results. Investors may watch how this divestiture affects growth mix, margins and future deal activity, along with upcoming earnings and capital allocation disclosures, to gauge the long‑term impact on the diagnostics and research portfolio.

Key Terms

biocompatibility testing, microbiological testing, preclinical research, regulatory consulting

4 terms

biocompatibility testing medical

"including biocompatibility testing, microbiological testing, analytical testing"

Biocompatibility testing evaluates whether a medical material, device, or drug ingredient is safe and non‑harmful when it touches or enters the body, checking for reactions such as irritation, toxicity, or immune response. Like a safety check for a new appliance before sale, successful testing is often required for regulatory approval, lowers the risk of costly recalls or legal problems, and affects how quickly a product can reach patients and generate revenue.

microbiological testing medical

"including biocompatibility testing, microbiological testing, analytical testing"

Microbiological testing is the process of checking products, raw materials, manufacturing environments or finished goods for bacteria, viruses, fungi and other tiny organisms that can cause contamination or spoilage. For investors it matters because test results affect product safety, regulatory approvals, production timelines and the risk of costly recalls or reputation damage—think of it as a security scan that prevents dangerous or defective goods from reaching customers.

preclinical research medical

"analytical testing, and preclinical research.This acquisition strengthens NAMSA's"

Preclinical research is the stage of drug or medical-device development where scientists test a candidate in the lab and in animals to assess safety, dosing and whether it works before giving it to humans. For investors, this phase is like a prototype being tested in a workshop: positive preclinical results reduce the unknowns and can increase a project’s value, while failures or unclear data signal higher risk and longer timelines to any potential return.

regulatory consulting regulatory

"device testing, clinical research, and regulatory consulting, is pleased to announce"

Regulatory consulting is professional advice and hands-on help that guides companies through government rules, approvals, filings and ongoing compliance—think of it as a map and translator between a business and regulators. Investors care because strong regulatory guidance can speed product launches, reduce the chance of fines or costly delays, and make future revenue and risks more predictable, affecting valuation and investment decisions.

AI-generated analysis. Not financial advice.

TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide.

As a result of the acquisition, NAMSA assumes the U.S. portfolio of services of Labcorp's Early Development medical device testing business, including biocompatibility testing, microbiological testing, analytical testing, and preclinical research.

This acquisition strengthens NAMSA's position as the industry's most comprehensive innovation partner for end-to-end medical device development, enabling clients to access expanded expertise and streamlined solutions across the product lifecycle.

Brian Smith, CEO of NAMSA notes: "This acquisition is a perfect fit for NAMSA - we serve 3,000+ MedTech companies globally in these specific areas of testing and preclinical research. I am confident we will be able to provide Labcorp's medical device clients with a smooth transition combined with the same high level of expertise and customer service current NAMSA clients have come to expect from us."  

NAMSA provides medical device testing, preclinical and clinical services, combined with comprehensive regulatory consulting to MedTech companies worldwide. The company has locations in the U.S., Europe and Asia. Future testing and preclinical projects for Labcorp's Early Development medical device clients will be performed at existing NAMSA facilities in Ohio, Minnesota, Georgia and California.

"The sale of our Early Development medical device testing business to NAMSA allows Labcorp to focus on core areas of preclinical drug development and chemical testing," said Brian Caveney, M.D., EVP and President, Early Development Research Laboratories, Labcorp. "We are pleased NAMSA will continue providing leading expertise to clients in this space and are committed to a seamless transition."

NAMSA is an ARCHIMED company; acquired by the healthcare-focused global private equity firm in 2020. This acquisition is NAMSA's 10^th acquisition since becoming an ARCHIMED company.

About NAMSA
Helping medical device Sponsors improve healthcare since 1967, NAMSA is a leading global MedTech testing, clinical and regulatory consulting firm. With a deep pool of testing, clinical and regulatory experts, and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development. From preclinical and clinical research to medical device testing and regulatory compliance, NAMSA is the industry's trusted partner for successful development and commercialization outcomes.
Learn more at namsa.com

About ARCHIMED
With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation. Learn more at archimed.group 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to the sale of Labcorp's Early Development medical device testing business to NAMSA and the potential benefits of the transaction. Actual results could differ materially from those suggested by forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Media Contacts:

NAMSA Media Contact 
Chris Schorre
Senior Director of Global Marketing
Email: communications@namsa.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/namsa-announces-strategic-acquisition-of-select-assets-of-the-early-development-medical-device-testing-business-of-labcorp-302655606.html

SOURCE NAMSA

FAQ

What did NAMSA acquire from Labcorp (NYSE: LH) on January 8, 2026?

NAMSA acquired the U.S. assets of Labcorp's Early Development medical device testing business, including biocompatibility, microbiological, analytical testing and preclinical research.

How will Labcorp's Early Development medical device projects be handled after the sale?

Future testing and preclinical projects for Labcorp's Early Development device clients will be performed at NAMSA facilities in Ohio, Minnesota, Georgia and California.

How does the acquisition affect NAMSA's market position and scale?

The acquisition expands NAMSA's U.S. service portfolio and reinforces its position as an end-to-end MedTech testing and development partner; it is NAMSA's 10th acquisition since joining ARCHIMED in 2020.

Will Labcorp continue in related businesses after selling the Early Development device testing assets?

Yes. Labcorp said the sale allows it to focus on core areas of preclinical drug development and chemical testing.

Who owns NAMSA and what scale of backing does that owner have?

NAMSA is owned by ARCHIMED, a healthcare-focused investment firm that manages €9 billion across its funds.